Home>
Stocks>
SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd (SMSPHARMA)

₹208.75▲6.18%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

SMS Pharmaceuticals Ltd share Performance

₹194.15
₹212.45
₹208.75
6.99%
Low
Day's Volatility:8.77%
High
1.77%
₹81.7
₹219.4
₹208.75
60.86%
Low
52 Weeks Volatility:65.96%
High
5.10%

Returns %
1 Month Return	-3.46 %
3 Month Return	50.48 %
1 Year Return	130.08 %

Market Stats
Previous Close	₹196.60
Open	₹196.00
Volume	5.53L
Upper Circuit	-
Lower Circuit	-
Market Cap	₹1,664.26Cr

Company Information

SMS Pharmaceuticals Limited is a public company founded in December 1987. Focused on manufacturing Active Pharmaceutical Ingredients and intermediates, the company has two facilities in Hyderabad and one in Vijayanagaram Dist. During 2015, the company successfully completed US FDA audits, filed nine Drug Master Files, and became an associate company of M/s. VKT Pharma Private Limited by acquiring 1,225,900 equity shares. During 2016-17, the company also acquired 511,400 shares in Sireen Drugs Private Limited and invested in SMS Lifesciences India Limited. 2017-18 saw the Scheme of Arrangement between Demerged and Resulting Companies, approved by Hon’ble National Company Law Tribunal and investment of 784,100 equity shares in VKT Pharma PVT LTD. In FY 2018-19, the company had 38,501,65 equity shares in VKT Pharma PVT LTD.

Share Price: ₹208.75 per share as on 07 May, 2024 04:01 PM
Market Capitalisation: ₹1,664.26Cr as of today
Revenue: ₹161.48Cr as on December 2023 (Q4 23)
Net Profit: ₹12.29Cr as on December 2023 (Q4 23)
Listing date: 28 Feb, 2007
Chairperson Name: P Ramesh Babu

Organisation	SMS Pharmaceuticals Ltd
Headquarters	Hyderabad
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Key events for SMS Pharmaceuticals Ltd

Retail Investors Profit as SMS Pharmaceuticals Surges 11% - 05 Apr, 2024
SMS Pharmaceuticals' considerable ownership by retail investors indicates they have a greater say in management and business strategy. Lack of institutional ownership may indicate disinterest due to earnings or other factors. Vamsi Potluri is the largest shareholder with 16% of shares outstanding, while insiders own a reasonable proportion of the company. The general public holds a 45% stake in SMS Pharmaceuticals.
SMS Pharmaceuticals Stock Soars 16% on Positive Business Outlook - 14 Mar, 2024
Shares of SMS Pharmaceuticals rose by 16% to Rs 189.95 on the BSE, driven by a positive business outlook and healthy financials. The company reported EBITDA growth of 56.7%, with revenue up 8.5% YoY at Rs 161.48 crore. Management is optimistic about future growth in the ibuprofen, anti-diabetic, and ARV segments, as well as new product offerings and capex investments.

Fundamentals of SMS Pharmaceuticals Ltd

Insights on SMS Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 64.32% to 64.67% in Mar 2024 quarter
POSITIVE IMPACT
Price Rise
In the last 3 months, SMSPHARMA stock has moved up by 50.5%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, SMSPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 0.00% to 1.98% in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 125.1% return, outperforming this stock by 98.3%
NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.59% to 0.17% in Mar 2024 quarter
NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 35.09% to 33.17% in Mar 2024 quarter
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 11.73 Cr → 11.48 Cr (in ₹), with an average decrease of 2.1% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 167.45 Cr → 162.97 Cr (in ₹), with an average decrease of 2.7% per quarter